Cannabis as an Adjunct to or Substitute for Opiates in the Treatment of Chronic Pain
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
There is a growing body of evidence to support the use of medical cannabis as an adjunct to or substitute for prescription opiates in the treatment of chronic pain. When used in conjunction with opiates, cannabinoids lead to a greater cumulative relief of pain, resulting in a reduction in the use of opiates (and associated side-effects) by patients in a clinical setting. Additionally, cannabinoids can prevent the development of tolerance to and withdrawal from opiates, and can even rekindle opiate analgesia after a prior dosage has become ineffective. Novel research suggests that cannabis may be useful in the treatment of problematic substance use. These findings suggest that increasing safe access to medical cannabis may reduce the personal and social harms associated with addiction, particularly in relation to the growing problematic use of pharmaceutical opiates. Despite a lack of regulatory oversight by federal governments in North America, community-based medical cannabis dispensaries have proven successful at supplying patients with a safe source of cannabis within an environment conducive to healing, and may be reducing the problematic use of pharmaceutical opiates and other potentially harmful substances in their communities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial
Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., & Petersen, K. L. (2007) · Neurology · doi:10.1212/01.wnl.0000253187.66183.9c · Cited by 598 · cited 3×
“In a study to determine the effect of smoked cannabis on pain related to HIV-associated sensory neuropathy and an experimental pain model, researchers found that smoked cannabis was well tolerated and effectively relieved chronic neuropathic pain (Abrams et al. 2007).”
BackgroundInfluentialCannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Smoked cannabis for chronic neuropathic pain: a randomized controlled trial
Ware, M. A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., Gamsa, A., Bennett, G. J., & Collet, J.-P. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.091414 · Cited by 450
Blake, D. R., Robson, P., Ho, M., Jubb, R. W., & McCabe, C. S. (2006) · Rheumatology · doi:10.1093/rheumatology/kei183 · Cited by 433 · cited 1×
“A study by Blake and colleagues (2006 ) examining the effects of Sativex, an oromucosal whole plant cannabis extract with a THC/CBD ratio of 50:50, on rheumatoid arthritis reported significant analgesic effect compared to placebo.”
Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., & Haines, D. (2007) · Pain · doi:10.1016/j.pain.2007.08.028 · Cited by 431 · cited 1×
“A clinical study by Nurmikko (2007 ) examining the effects of Sativex as an adjunct to existing stable analgesia in patients suffering from peripheral neuropathic pain showed that 26% of participants reported more than 30% reductions in pain intensity, compared with 15% in those using placebo.”
ResultNabilone for the treatment of pain in fibromyalgia.
Skrabek, R. Q., Galimova, L., Ethans, K., & Perry, D. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.002 · Cited by 384 · cited 1×
“A randomized clinical study by Skrabek and colleagues (2008 ) on nabilone as an adjunct treatment for 15 patients affected by fibromyalgia reported significant benefits in pain and overall function.”
BackgroundWagner, F. A. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.10.918 · Cited by 380 · cited 2×
“While most studies have focused on the social or economic determinants that could lead cannabis users to experiment with other substances ( Wagner & Anthony 2002 ; Pacula et al.”
BackgroundThe analgesic properties of delta‐9‐tetrahydrocannabinol and codeine
Noyes, R., Brunk, S. F., Avery, D. H., & Canter, A. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518184 · Cited by 378 · cited 2×
“The results suggest that 10 mg THC was slightly less effective than 60 mg codeine, and that 20 mg THC was slightly more effective than 120 mg of codeine (Noyes et al. 1975b).”
BackgroundA randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain
Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., & Fishman, S. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.12.010 · Cited by 327
Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy
Narang, S., Gibson, D., Wasan, A. D., Ross, E. L., Michna, E., Nedeljkovic, S. S., & Jamison, R. N. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.10.018 · Cited by 257 · cited 1×
“Narang and colleagues (2008 ) conducted a phase 1 and phase 2 study examining the efficacy of dronabinol as an adjunct to opioid therapy for the treatment of chronic pain.”
BackgroundThe globalization of ayahuasca: harm reduction or benefit maximization?
Tupper, K. W. (2008) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2006.11.001 · Cited by 212
Antinociceptive Synergy between Δ9-Tetrahydrocannabinol and Opioids after Oral Administration
Cichewicz, D. L., & McCarthy, E. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045575 · Cited by 154
Maurer, M., Henn, V., Dittrich, A., & Hofmann, A. (1990) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02190083 · Cited by 117 · cited 1×
“The only major reported difference between the active drugs was that THC relieved spasticity better than codeine (Maurer et al. 1990).”
BackgroundCichewicz, D. L., & Welch, S. P. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046870 · Cited by 110
Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., & Pölz, W. (2006) · Wiener klinische Wochenschrift · doi:10.1007/s00508-006-0611-4 · Cited by 96 · cited 1×
“A study by Pinsger (2006 ) on the effects of nabilone (a synthetic cannabinoid) as an adjunct to existing chronic pain therapy resulted in reduced pain and improved quality of life.”
BackgroundReassessment of the role of cannabinoids in the management of pain
Beaulieu, P., & Ware, M. (2007) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e3282efd175 · Cited by 34
Cited by
Consensus on current management of endometriosis
Johnson, N. P., Hummelshoj, L., for the World Endometriosis Society Montpellier Consortium, Abrao, M. S., Adamson, G. D., Allaire, C., Amelung, V., Andersson, E., Becker, C., Birna Árdal, K. B., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det050 · Cited by 558
Jin, D., Dai, K., Xie, Z., & Chen, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-60172-6 · Cited by 348
Lucas, P., & Walsh, Z. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.01.011 · Cited by 271
Self-citationTapering opioids: a comprehensive qualitative review
Davis, M. P., Digwood, G., Mehta, Z., & McPherson, M. L. (2020) · Annals of Palliative Medicine · doi:10.21037/apm.2019.12.10 · Cited by 33
Tripp, D. A., Nickel, J. C., Katz, L., Krsmanovic, A., Ware, M. A., & Santor, D. (2014) · Canadian Urological Association Journal · doi:10.5489/cuaj.2268 · Cited by 22
Metadata
- Authors
- Lucas, P.
- Venue
- Journal of Psychoactive Drugs
- Publisher
- Informa UK Limited
- Published
- 2012-04
- Volume
- 44
- Issue
- 2
- Pages
- 125-133
- ISSN
- 0279-1072 (ISSN-L)
- 2159-9777
- OpenAlex
- W2153245799
- Cited by
- 131
- References
- 16
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.